Marinus Pharmaceuticals, Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Regeneron Bolsters Ophthalmic Portfoli

The tally of biopharmaceutical companies that have gone public in the US in 2024 has now surpassed not only last year’s total but the total from 2022 now that Septerna Inc. has launched its IPO, gross

Marinus Pharmaceuticals, Inc. got mixed results on 17 June from a Phase III trial of the intravenous formulation of neuroactive steroid ganaxolone in the rare severe seizure condition refractory stat

Verona Pharma plc entered into agreements that give the company access to as much as $650m in new debt and other financing, bringing its new cash potential to more than $1bn after starting the year w